Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 58 publications.

Karim S, Craig BM, Vass C, Groothuis-Oudshoorn CGM. Current practices for accounting for preference heterogeneity in health-related discrete choice experiments: a systematic review. Pharmacoeconomics. 2022 Oct 1;40(10):943-56. doi: 10.1007/s40273-022-01178-y

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022 Jun;40(6):601-32116. doi: 10.1007/s40273-021-01112-8

Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom. Pharmacoeconomics. 2022 Mar;40(3):323-39.

Dorgali MV, Longo A, Vass C, Shields G, Harrison R, Scarpa R, Boeri M. A general public study on preferences and welfare impacts of antimicrobial resistance in the United Kingdom. Pharmacoeconomics. 2022 Jan;40(1):65-76. doi: 10.1007/s40273-021-01076-9

Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32. doi: 10.1007/s40273-020-00992-6

Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, Knight C, Wilson M. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021 Jan;39(1):121-31. doi: 10.1007/s40273-020-00976-6

Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. The budget impact of introducing tildrakizumab to a United States health plan for managing moderate-to-severe plaque psoriasis. Pharmacoeconomics. 2020 Mar 26.

Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, Forsmark A, Vickers AD, Lloyd A. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019 Jun;37(6):845-65. doi: 10.1007/s40273-019-00769-6

Soekhal V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019 Feb;37(2):201-26. doi: 10.1007/s40273-018-0734-2

Emery P, van Keep M, Beard S, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics. 2018 Aug;36(8):1015-27. doi: 10.1007/s40273-018-0675-9

Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.

Vass CM, Payne K. Using discrete choice experiments to inform the benefit-risk assessment of medicines: are we ready yet? Pharmacoeconomics. 2017 Sep;35(9):859-66. doi: 10.1007/s40273-017-0518-0.

Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017 May;35(5):517-35. doi: 10.1007/s40273-017-0486-4

Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016 Nov;34(11):1111-31. doi: 10.1007/s40273-016-0426-8

Tappenden P, Ren S, Archer R, Harvey R, James MM, Basarir H, Stevens J, Lobo A, Hoque S. A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventional therapy. Pharmacoeconomics. 2016 Oct;34(10):1023-38. doi: 10.1007/s40273-016-0409-9.

Graham J, Mcbride D, Stull D, Halliday A, Alexopoulos ST, Balp MM, Griffiths M, Agirrezabal I, Zuberbier T, Brennan A. Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria. Pharmacoeconomics. 2016 Aug;34(8):815-27. doi: 10.1007/s40273-016-0412-1

Hawe E, Mcbride D, Balp MM, Tian H, Halliday A, Stull DE. EQ-5D utilities in chronic spontaneous/idiopathic urticaria. Pharmacoeconomics. 2016 May;34(5):521-7. doi: 10.1007/s40273-015-0375-7

Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K. Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada. Pharmacoeconomics. 2016 Jan;34(1):77-90. doi: 10.1007/s40273-01509332-5

Poonawalla IB, Parikh RC, Du XL, VonVille HM, Lairson DR. Cost effectiveness of chemotherapeutic agents and targeted biologics in ovarian cancer: a systematic review. Pharmacoeconomics. 2015 Nov;33(11):1155-85. doi: 10.1007/s40273-015-0304-9

Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014 Oct;32(10):1005-13.

Brogan AJ, Smets E, Mauskopf JA, Manuel SA, Adriaenssen I. Cost-effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. Pharmacoeconomics. 2014 Sep;32(9):903-17.

Mauskopf J. Modelling technique, structural assumptions, input parameter values: which has the most impact on the results of a cost-effectiveness analysis? Pharmacoeconomics. 2014 Jun;32(6):521-3. doi: 10.1007/s40273-014-0157-7

Mauskopf J, Samuel M, Mcbride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014 Apr;32(4):395-409.

Mauskopf J. A methodological review of models used to estimate the cost effectiveness of antiretroviral regimens for the treatment of HIV infection. Pharmacoeconomics. 2013 Nov;31(11):1031-50.

Earnshaw SR, Brogan AP, McDade CL. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics. 2013 Apr 1;31(4):289-304.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013 Mar 1;Advance Online.

Mauskopf J, Brodan A, Martin S, Smets E. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2012 Oct;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000

Talbird SE, Mauskopf J, Smets E, Brogan AJ. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010 Dec 23;28(Suppl 1):129-46.

Mauskopf J, Annemans L, Hill AM, Smets E. A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection. Pharmacoeconomics. 2010 Dec 23;28(Suppl 1):1-16.

Colin X, Lafuma A, Costagliola D, Smets E, Mauskopf J, Guillon P. Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France. Pharmacoeconomics. 2010 Dec 23;28(Suppl 1):183-97.

Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.

Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics. 2007 Oct 1;25(10):863-79.

Shih YCT, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics. 2007 Jul 1;25(7):577-90.

Bala MV, Mauskopf JA. Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts. Pharmacoeconomics. 2006 Apr 1;24(4):345-54.

Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004 Jan 1;22(4):207-24.

Bann CM, Fehnel S, Gagnon DD. Development and validation of the diabetic foot ulcer scale-short form (DFS-SF). Pharmacoeconomics. 2003 Jan 1;21(17):1277-90.

Mauskopf JA, Rutten F, Schonfeld W. League tables: valuable guidance for decision makers. Pharmacoeconomics. 2003;21(14):991-1000.

Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics. 2003 Jan 1;21(12):839-51.

Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics. 2003 Jan 1;21(14):991-1000.

McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003 Jan 1;21(15):1069-79.

Richter A, Hauber B, Simpson K, Mauskopf JA, Yin D. A Monte Carlo simulation for modelling outcomes of AIDS treatment regimens. Pharmacoeconomics. 2002 Jan 1;20(4):215-24.

Hauber AB, Mauskopf JA, Snyder EH. Potential savings in the cost of caring for Alzheimer's disease treatment with rivastigmine - Reply. Pharmacoeconomics. 2000 Dec 1;18(6):610-2.

Mauskopf JA, Richter A, Annemans L, Maclaine G. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Pharmacoeconomics. 2000 Sep 1;18(3):239-51.

Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost-effectiveness of zanamivir for the treatment of influenza in a high-risk population in Australia. Pharmacoeconomics. 2000 Jun;17(6):611-20. doi: 10.2165/00019053-200017060-00007.

Sculpher M, Palmer MK, Heyes AE. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000 Apr;17(4):361-70.

Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for alzheimer's disease: treatment with rivastigmine. Pharmacoeconomics. 2000 Apr 1;17(4):351-60.

McKenna SP, Doward LC. A review of quality of life in Alzheimer's disease. Parts 1 and 2: issues in assessing disease impact and drug effects. Pharmacoeconomics. 1999 Oct;16(4):417-9.

Mauskopf JA, Cates SC, Griffin AD. A pharmacoeconomic model for the treatment of influenza. Pharmacoeconomics. 1999 Jan;16(Suppl 1):73-84.

Bala MV, Mauskopf JA, Wood LL. Willingness to pay as a measure of health benefits. Pharmacoeconomics. 1999 Jan 1;15(1):9-18.